Understanding step therapy requirements: what your team needs to know in September 2026

If there's one prior authorization requirement that consistently frustrates both clinical staff and billing teams, it's step therapy. A physician prescribes what they believe is clinically appropriate, and the insurer responds by requiring the patient to "fail first" on a cheaper alternative before the plan will cover what was actually ordered. It delays care, burns staff time, and sometimes puts patients in genuinely difficult positions. Step therapy isn't going away, and as of mid-2026 the regulatory environment around it has gotten more layered than ever. Understanding how it works, where exceptions apply, and how to document effectively can mean a clean approval instead of a weeks-long battle.

What step therapy actually is and why payers use it

Step therapy, sometimes called "fail first," is a utilization management strategy where insurers require patients to try one or more lower-cost or preferred formulary medications before approving coverage for a more expensive option. From a payer's perspective, the logic is straightforward: why pay for a brand-name biologic if a generic or preferred agent might work just as well?

In practice, you've probably seen how this plays out. A rheumatologist prescribes a specific JAK inhibitor based on a patient's comorbidities and prior treatment history. The plan requires two failed trials of conventional DMARDs first. The patient may have already failed those drugs years ago under a different insurer, but because the documentation isn't in the current claims system, you're starting from scratch.

The key point for your team: step therapy is a documentation and communication challenge as much as it is a clinical one. The medical rationale usually exists. Getting it in front of the right reviewer, in the right format, is where the work happens.

What's changed in 2026

The step therapy space has continued to shift. Several states have strengthened their step therapy exception laws over the past few years, and federal guidance has pushed commercial plans and Medicare Advantage organizations toward clearer timelines and more defined exception processes.

A few things worth tracking right now:

• Medicare Advantage plans are under increased CMS scrutiny for inappropriate step therapy application, particularly for Part B drugs. Unusual denials in this space are worth a closer look to confirm the plan's criteria actually align with CMS guidance.


• State-level protections vary significantly. Some states have strong exception frameworks requiring insurers to grant an exception when a physician certifies the step therapy requirement would be contraindicated, ineffective, or cause harm. Others offer minimal protection. Know your state's rules.


• Timelines matter more now. Many updated regulations specify that step therapy exception requests must be processed within 72 hours, or 24 hours for urgent cases. If a payer is sitting on a request beyond those windows, you may have grounds for escalation.

It's also worth knowing that "step therapy override" is increasingly standard language in payer contracts. If your practice hasn't reviewed payer agreements with this in mind recently, that's a conversation worth having with your contracting team.

Building a strong step therapy exception request

This is where most teams leave points on the table. A weak exception request gets denied. A well-constructed one often gets approved on the first submission.

Core components of a solid exception request:

• Clinical contraindication documentation: If the required step drug is contraindicated for your patient, state it clearly and attach supporting diagnosis codes, labs, or clinical notes. Don't assume the reviewer will connect the dots.


• Prior treatment history: If the patient already failed the required step drug, whether under your care or a previous provider, you need that documentation. Discharge summaries, records requests, and specialist notes all qualify.


• Formulary exceptions based on clinical evidence: Some payers will accept peer-reviewed literature supporting the prescribed agent as superior for a specific patient population. It takes more work, but it's a legitimate pathway.


• Physician attestation: A letter from the treating physician explaining why skipping the step is medically necessary carries real weight. It doesn't need to be long. It needs to be specific.

One thing that makes a measurable difference: framing the exception around the patient's individual clinical circumstances rather than making a general argument about the drug. Reviewers are looking for reasons to approve. Give them something concrete to hang an approval on.

Common mistakes that lead to unnecessary denials

Even experienced billing teams run into these patterns.

Incomplete appeals. Submitting an appeal without attaching the clinical documentation is the most common avoidable error. The denial letter will read "clinical information not on file," and you've lost time you didn't have.

Missing the step therapy override language. If your state has a step therapy exception law, your appeal should reference it explicitly. Payers respond differently when they know you know the rules.

Not escalating fast enough. When a step therapy denial is affecting active treatment, particularly for oncology, autoimmune conditions, or mental health, escalate to peer-to-peer review quickly. Many physicians are reluctant to do peer-to-peers, but they work. Train your clinical staff to prioritize these calls.

Treating every denial the same way. Step therapy denials follow different pathways than coverage exclusions or medical necessity denials. Make sure your team knows which workflow applies.

Tools and resources that actually help

Managing step therapy exception requests manually at any real volume is genuinely hard. Documentation requirements are detailed, timelines are tight, and payer-specific criteria change frequently.

A few practical resources worth building into your workflow:

• Payer-specific step therapy criteria sheets: Keep a running reference document for your top payers that outlines their step therapy requirements by drug class. It reduces back-and-forth and cuts lookup time considerably.


• Template appeal letters: Not generic ones. Templates structured around the actual exception criteria payers use, with clear fields for clinical specifics.


• AI-powered appeal generation tools: These have become genuinely useful. Tools like EZAppeal can help your team draft medically grounded, payer-aware appeal letters much faster than starting from scratch, which matters when you're juggling volume.


• State insurance department resources: Most state insurance commissioners publish step therapy regulations and complaint procedures. Bookmark these. They're useful when a payer is clearly out of compliance.

Putting it all together

Step therapy requirements aren't going to get simpler. As specialty drug spend keeps rising, payers will lean on utilization management harder, not less. The practices and RCM teams that handle this well treat step therapy exceptions as a structured, repeatable process rather than a one-off fire drill.

Start with a quick audit of your current step therapy denial volume. What drug classes are driving it? Which payers are you seeing it from most? That data will tell you where to focus your documentation improvements and where you may need to revisit your prior auth workflows entirely.